Immunotech Biopharm Ltd (HK:6978)
:6978
Top Page
Immunotech Biopharm Ltd
(6978)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$2.50
▼(-6.72% Downside)
Action:UpgradedDate:12/30/25
The score is weighed down primarily by weak financial fundamentals—no revenue, ongoing losses/negative free cash flow, and a high-risk balance sheet with negative equity and elevated debt. Technicals also point to a continued downtrend, while valuation support is limited due to negative earnings and no dividend data.
Positive Factors
Trend in loss reduction
The substantial reduction in net loss year-over-year signals improving cost control or scaled-back spend. Persistently narrowing losses can extend runway and reduce near-term financing urgency, which materially lowers execution risk and supports continued R&D progress over the next several quarters.
Negative Factors
Pre-revenue model
With no revenue history, the company’s business viability depends entirely on future product commercialization and trial success. This raises structural execution risk, limits internal funding capacity, and keeps the company reliant on external capital and binary clinical/regulatory outcomes for long-term sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Trend in loss reduction
The substantial reduction in net loss year-over-year signals improving cost control or scaled-back spend. Persistently narrowing losses can extend runway and reduce near-term financing urgency, which materially lowers execution risk and supports continued R&D progress over the next several quarters.
Read all positive factors
Immunotech Biopharm Ltd (6978) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.68B
Dividend YieldN/A
Average Volume (3M)1.34M
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue GrowthN/A
EPS Growth27.90%
CountryHK
Employees154
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.19
Shares Outstanding617,500,800
10 Day Avg. Volume1,608,107
30 Day Avg. Volume1,338,788
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-83.60
Price to Sales (P/S)0.00
P/FCF Ratio-7.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Immunotech Biopharm Ltd Business Overview & Revenue Model
Company Description
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core prod...
How the Company Makes Money
Immunotech Biopharm Ltd generates revenue through the development and commercialization of its proprietary cellular immunotherapy products. The company's primary revenue streams include the sale of its approved therapies and treatments to healthca...
Immunotech Biopharm Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -122.01M | -148.68M | -178.83M | -231.11M | -324.33M | -333.99M |
| Net Income | -223.50M | -186.91M | -334.82M | -318.11M | -354.22M | -439.05M |
Balance Sheet | ||||||
| Total Assets | 488.90M | 564.04M | 846.28M | 879.44M | 1.10B | 1.21B |
| Cash, Cash Equivalents and Short-Term Investments | 21.05M | 57.49M | 176.97M | 79.46M | 353.34M | 845.39M |
| Total Debt | 111.73M | 384.56M | 784.01M | 149.81M | 111.05M | 51.06M |
| Total Liabilities | 634.38M | 580.50M | 675.39M | 373.07M | 274.51M | 81.38M |
| Stockholders Equity | -142.40M | -13.30M | 173.62M | 508.44M | 822.26M | 1.13B |
Cash Flow | ||||||
| Free Cash Flow | -53.83K | -153.81M | -186.17M | -277.49M | -435.89M | -339.34M |
| Operating Cash Flow | -46.23K | -125.74M | -163.63M | -180.92M | -254.65M | -263.67M |
| Investing Cash Flow | 23.43K | 141.10M | -116.60M | 23.38M | -328.21M | -204.07M |
| Financing Cash Flow | -9.91K | -20.59M | 273.92M | -36.06M | -11.00M | 1.05B |
Immunotech Biopharm Ltd Technical Analysis
Positive
2.68
Price Trends
2.57
Positive
2.78
Negative
3.31
Negative
Market Momentum
0.04
Negative
56.70
Neutral
76.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6978, the sentiment is Positive. The current price of 2.68 is above the 20-day moving average (MA) of 2.58, above the 50-day MA of 2.57, and below the 200-day MA of 3.31, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 56.70 is Neutral, neither overbought nor oversold. The STOCH value of 76.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6978.
Immunotech Biopharm Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.86B | -16.66 | 0.99% | ― | 9.41% | -32.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$1.67B | -4.01 | -12.64% | ― | -38.38% | -22.12% | |
45 Neutral | HK$2.42B | -14.44 | -27.70% | ― | -100.00% | 30.68% | |
44 Neutral | HK$1.96B | -3.21 | -184.99% | ― | ― | -18.99% | |
44 Neutral | HK$1.01B | -18.55 | -15.19% | ― | ― | 22.65% | |
43 Neutral | HK$1.68B | -6.43 | 293.08% | ― | ― | 27.90% |
* Healthcare Sector Average
HK:6978
Immunotech Biopharm Ltd
2.72
-0.40
-12.82%
HK:1875
TOT BIOPHARM International Co. Ltd.
5.00
3.41
214.47%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
4.10
-2.90
-41.43%
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
4.13
2.27
122.04%
HK:3681
SinoMab Bioscience Ltd.
1.76
0.59
50.43%
HK:6622
Zhaoke Ophthalmology Ltd.
3.04
1.58
108.22%
Immunotech Biopharm Ltd Corporate Events
Immunotech Biopharm Subsidiary Signs RMB9.75 Million Cell Therapy Service Deal With Tasly
Jan 27, 2026
Immunotech Biopharm Ltd, a Hong Kong-listed biopharmaceutical company, develops and processes cell therapies and related services, leveraging its subsidiary Yongtai Beijing’s GMP-compliant facilities and technical expertise in cell product p...
Immunotech Biopharm Moves to Refinance 2023 Convertible Bonds via New Issue
Jan 20, 2026
Immunotech Biopharm Ltd has entered into a legally binding framework agreement with the existing holder of its 2023 Convertible Bonds for the subscription of new convertible bonds and a note, with the entire consideration to be used to fully settl...
Immunotech Biopharm Ltd Engages in Strategic Financial Investment
Dec 8, 2025
Immunotech Biopharm Ltd has announced a discloseable transaction involving the subscription of structured deposit products from Bank of China Limited, with a total investment value of RMB120,000,000. This strategic financial move is subject to the...
Immunotech Biopharm Ltd’s Rights Issue Oversubscribed, Raising HK$257.29 Million
Nov 12, 2025
Immunotech Biopharm Ltd announced the successful completion of its rights issue, which was significantly oversubscribed. The company raised approximately HK$257.29 million in gross proceeds, with net proceeds estimated at HK$251.88 million, which ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.